Adefovir
- Generic Name
- Adefovir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N5O4P
- CAS Number
- 106941-25-7
- Unique Ingredient Identifier
- 6GQP90I798
- Associated Conditions
- -
- Associated Therapies
- -
Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 62
- Registration Number
- NCT03801759
- Locations
- 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada
Drug Transporter Interaction Study PHENTRA_2015_KPUK
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 24
- Registration Number
- NCT02743260
- Locations
- 🇩🇪
Department of Pharmacology I, University Hospital Cologne, Cologne, NRW, Germany
An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 324
- Registration Number
- NCT02560649
Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02482272
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT02366208
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
🇨🇳The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 463
- Registration Number
- NCT02366247
- Locations
- 🇨🇳
Yanbian University Hospital, Yanbian, Jilin, China
🇨🇳Tangdu Hospital, Xi'an, Shanxi, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2013-02-26
- Lead Sponsor
- Lin Bingliang
- Target Recruit Count
- 300
- Registration Number
- NCT01799486
An Study of Efficacy and Safety of Clevudine
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 288
- Registration Number
- NCT01192854
- Locations
- 🇨🇳
Xiangya hospital, Changsha, Hunan, China
A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive
- Conditions
- Interventions
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 265
- Registration Number
- NCT01086085
Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT01023217
- Locations
- 🇰🇷
Asan Medical Center, Seoul, the Meteropolis of Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.